This pilot study focuses on assessing the suitability and potential effectiveness of ketamine, a glutamate modulator, as a rapid treatment option for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults. Targeting a specific group of 6 individuals aged 14 to 22 with clinically significant OCD, the study seeks participants who have not responded adequately to at least one Serotonin Reuptake Inhibitor (SRI) medication and a course of Cognitive-Behavioral Therapy (CBT), unless these treatments were inaccessible or intolerable. Each participant will undergo a single session of intravenous ketamine infusion, followed by regular assessments over a 14-day period to monitor the treatment's efficacy. After this initial treatment phase, all participants will be offered a three-month open treatment program for OCD, which may include medication, CBT, or a combination of both. This approach aims to explore ketamine's role as a fast-acting therapeutic alternative for young individuals grappling with OCD, especially those who have found limited relief from conventional treatments.